Carlsmed (CARL) vs Neuropace (NPCE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Neuropace (NPCE) has outperformed Carlsmed (CARL) over the past year, gaining 19.8% versus a gain of 5.8%. Neuropace is the larger company by market cap ($424.1 million vs $382.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CARL | NPCE |
|---|---|---|
| Share price | $14.01 | $12.36 |
| Market cap | $382.51M | $424.08M |
| 1-day change | -2.57% | -3.18% |
| YTD return | +16.44% | -17.36% |
| 1-year return | +5.81% | +19.81% |
| 5-year return | — | -18.57% |
| EPS (TTM) | $-1.08 | $-0.57 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.23 | $19.60 |
| 52-week low | $8.50 | $9.22 |
| Distance from 52-week high | -18.69% | -36.96% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +37.04% | +61.88% |
| Average volume | 125.43K | 169.86K |
| Shares outstanding | 27.30M | 34.32M |
| Employees | 127 | 220 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NPCE has outperformed CARL by 14.0 percentage points over the past year.
About Carlsmed
CARL stock →Carlsmed, Inc., a commercial-stage medical technology company, designs, manufactures, and markets AI-enabled personalized spine surgery solutions. The company develops aprevo, a comprehensive technology platform for spine fusion surgery procedures.
Health Care · Medical/Dental Instruments · 127 employees
About Neuropace
NPCE stock →NeuroPace, Inc. operates as a medical device company in the United States.
Health Care · Medical/Dental Instruments · 220 employees
CARL vs NPCE FAQ
Which is bigger, Carlsmed or Neuropace?
Neuropace (NPCE) is larger, with a market capitalization of $424.08M compared with $382.51M for Carlsmed (CARL).
Which stock has performed better over the past year, CARL or NPCE?
NPCE returned +19.81% over the past 12 months, compared with +5.81% for CARL (price return, excluding dividends). Past performance does not predict future results.
Are Carlsmed and Neuropace in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.